Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension

Dow Jones

Mar 10, 2025

By Colin Kellaher

Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.

Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile.

The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension.

Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

March 10, 2025 07:19 ET (11:19 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2518242602"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518242602\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2518242602?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 19:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518242602","market":"sh","top_or_hot":-1,"title":"Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension. \n</p>\n<p>\n  Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile. \n</p>\n<p>\n  The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension. \n</p>\n<p>\n  Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 07:19 ET (11:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMineralys Posts Positive Lorundrostat Study Results for Uncontrolled Hypertension\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-10 19:19</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  Mineralys <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension. \n</p>\n<p>\n  Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile. \n</p>\n<p>\n  The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension. \n</p>\n<p>\n  Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 07:19 ET (11:19 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MLYS","symbol_name":"Mineralys Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2518242602","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518242602","pubTimestamp":1741605540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension.Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile.The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension.Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MLYS":"Mineralys Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Mineralys发布Lorundrostat治疗未控制高血压的积极研究结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLYS":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Mineralys Therapeutics on Monday reported positive topline results from a pair of pivotal studies of its lorundrostat drug candidate for the treatment of uncontrolled or resistant hypertension. \n\n\n  Mineralys said its Phase 3 Launch-HTN and Phase 2 Advance-HTN studies achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints while showing a favorable safety and tolerability profile. \n\n\n  The Radnor, Pa., clinical-stage biopharmaceutical company said it believes the clinical profile observed for lorundrostat supports the potential regulatory approval of the drug, which it said has the potential to be a transformative new therapy for the roughly 15 million to 20 million people in the U.S. living with uncontrolled hypertension. \n\n\n  Trading in shares of Mineralys, which closed Friday at $10.52, was halted premarket on Monday. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:19 ET (11:19 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}